Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 243 results:
Συντάκτης Τίτλος Τύπος [ Έτος![(Desc)](https://www.med.auth.gr/sites/all/modules/biblio/misc/arrow-desc.png)
Φίλτρα: Συντάκτης is Karagiannis, Asterios [Clear All Filters]
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis..
Arch Med Sci. 7(6), 984-92.
(2011). Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?.
Open Cardiovasc Med J. 5, 226-30.
(2011). Residual cardiac risk reduction beyond lipid lowering..
Hellenic J Cardiol. 52(3), 197-203.
(2011).
(2011).
(2011). The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings..
Arch Med Sci. 8(1), 6-10.
(2012). Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?.
Curr Vasc Pharmacol. 10(3), 374-7.
(2012). Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance..
J Clin Lipidol. 6(1), 93.
(2012). Fibrinogen, hematocrit, and platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study..
Clin Appl Thromb Hemost. 18(1), 113-4.
(2012). Lipid lowering agents and the endothelium: an update after 4 years..
Curr Vasc Pharmacol. 10(1), 33-41.
(2012). Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis..
Angiology. 63(5), 358-66.
(2012). Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome..
Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
(2012). Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease..
Dig Dis Sci. 57(4), 1109.
(2012). Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options..
Curr Vasc Pharmacol. 10(2), 162-72.
(2012). Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity..
Am J Cardiol. 110(5), 763.
(2012). Response to 'Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome'..
Clin Cardiol. 35(5), 315; author reply 316-7.
(2012). Should raising high-density lipoprotein cholesterol be a matter of debate?.
J Cardiovasc Med (Hagerstown). 13(4), 254-9.
(2012). Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial..
J Hepatol. 57(2), 476.
(2012). Stage of chronic kidney disease and severity of coronary heart disease manifestation..
Expert Opin Pharmacother. 13(4), 457-60.
(2012). Therapeutic options for statin-intolerant patients..
Curr Med Res Opin. 28(3), 345-9.
(2012). Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?.
Open Cardiovasc Med J. 6, 28-32.
(2012).
(2012). 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?.
Metabolism. 62(1), 21-33.
(2013). Alcohol consumption and the heart..
Int J Cardiol. 168(4), 4319.
(2013). Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients..
Curr Med Res Opin. 29(7), 791-2.
(2013).